Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - NEUROLOGIX INC/DE | v224205_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - NEUROLOGIX INC/DE | v224205_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 26, 2011
Neurologix, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
000-13347
|
06-1582875
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification Number)
|
One Bridge Plaza, Fort Lee, New Jersey 07024
(Address of principal executive offices)
(201) 592-6451
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Disclosure.
On May 26, 2011, Michael G. Kaplitt, M.D., Ph.D., one of the scientific co-founders of Neurologix, Inc., is making a presentation at the International Neuromodulation Society 10th World Congress in London, England. Such presentation will include a discussion and slide show presentation of previously unreported one-year efficacy results of Neurologix, Inc.’s Phase 2 trial for Parkinson’s disease. A copy of the slides related to such results, substantially in the form to be used by Dr. Kaplitt, is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
On May 26, 2011, Neurologix, Inc. issued a press release regarding Dr. Kaplitt’s presentation at the International Neuromodulation Society 10th World Congress in London, England, as described above. A copy of the press release is being furnished as Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are furnished herewith:
Exhibit
|
Number
|
Description
|
|
99.1
|
Slides related to one-year efficacy results of Neurologix, Inc’s Phase 2 trial for Parkinson’s disease (furnished pursuant to Item 7.01 of Form 8-K).
|
|
99.2
|
Press Release of Neurologix, Inc., dated May 26, 2011 (furnished pursuant to Item 7.01 of Form 8-K).
|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NEUROLOGIX, INC.
|
|||||
|
Date: May 26, 2011
|
By:
|
/s/ Marc L. Panoff
|
|||
|
Name: Marc L. Panoff
|
|||||
|
Title: Chief Financial Officer, Secretary and Treasurer
|
|||||
EXHIBIT INDEX
|
Exhibit
|
Description
|
|
99.1
|
Slides related to one-year efficacy results of Neurologix, Inc’s Phase 2 trial for Parkinson’s disease (furnished pursuant to Item 7.01 of Form 8-K).
|
|
99.2
|
Press Release of Neurologix, Inc., dated May 26, 2011 (furnished pursuant to Item 7.01 of Form 8-K).
|